Randomized Trial: Treatments for Relapsed Glioblastoma Compared
4 Jan, 2019 | 20:27h | UTCRegorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Regorafenib vs Lomustine in Relapsed Glioblastoma – The ASCO Post (free)